Literature DB >> 29939936

ACOG Committee Opinion No. 743 Summary: Low-Dose Aspirin Use During Pregnancy.

.   

Abstract

Low-dose aspirin has been used during pregnancy, most commonly to prevent or delay the onset of preeclampsia. The American College of Obstetricians and Gynecologists issued the Hypertension in Pregnancy Task Force Report recommending daily low-dose aspirin beginning in the late first trimester for women with a history of early-onset preeclampsia and preterm delivery at less than 34 0/7 weeks of gestation, or for women with more than one prior pregnancy complicated by preeclampsia. The U.S. Preventive Services Task Force published a similar guideline, although the list of indications for low-dose aspirin use was more expansive. Daily low-dose aspirin use in pregnancy is considered safe and is associated with a low likelihood of serious maternal, or fetal complications, or both, related to use. The American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine support the U.S. Preventive Services Task Force guideline criteria for prevention of preeclampsia. Low-dose aspirin (81 mg/day) prophylaxis is recommended in women at high risk of preeclampsia and should be initiated between 12 weeks and 28 weeks of gestation (optimally before 16 weeks) and continued daily until delivery. Low-dose aspirin prophylaxis should be considered for women with more than one of several moderate risk factors for preeclampsia. Women at risk of preeclampsia are defined based on the presence of one or more high-risk factors (history of preeclampsia, multifetal gestation, renal disease, autoimmune disease, type 1 or type 2 diabetes, and chronic hypertension) or more than one of several moderate-risk factors (first pregnancy, maternal age of 35 years or older, a body mass index greater than 30, family history of preeclampsia, sociodemographic characteristics, and personal history factors). In the absence of high risk factors for preeclampsia, current evidence does not support the use of prophylactic low-dose aspirin for the prevention of early pregnancy loss, fetal growth restriction, stillbirth, or preterm birth.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29939936     DOI: 10.1097/AOG.0000000000002709

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  9 in total

1.  The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention.

Authors:  Liona C Poon; Andrew Shennan; Jonathan A Hyett; Anil Kapur; Eran Hadar; Hema Divakar; Fionnuala McAuliffe; Fabricio da Silva Costa; Peter von Dadelszen; Harold David McIntyre; Anne B Kihara; Gian Carlo Di Renzo; Roberto Romero; Mary D'Alton; Vincenzo Berghella; Kypros H Nicolaides; Moshe Hod
Journal:  Int J Gynaecol Obstet       Date:  2019-05       Impact factor: 3.561

Review 2.  Fetal Supraventricular Tachycardia: What the Adult Cardiologist Needs to Know.

Authors:  Sutopa Purkayastha; Michael Weinreich; Joao D Fontes; Joe F Lau; Diana S Wolfe; Anna E Bortnick
Journal:  Cardiol Rev       Date:  2022 Jan-Feb 01       Impact factor: 2.644

3.  First-trimester maternal serum alpha-fetoprotein is not a good predictor for adverse pregnancy outcomes: a retrospective study of 3325 cases.

Authors:  Jilin Hu; Jinman Zhang; Guilin He; Shu Zhu; Xinhua Tang; Jie Su; Qian Li; Yamin Kong; Baosheng Zhu
Journal:  BMC Pregnancy Childbirth       Date:  2020-02-12       Impact factor: 3.007

4.  Antepartum Aspirin Administration Reduces Activin A and Cardiac Global Longitudinal Strain in Preeclamptic Women.

Authors:  Heba Naseem; John Dreixler; Ariel Mueller; Avery Tung; Rohin Dhir; Rachna Chibber; Abid Fazal; Joey P Granger; Bhavisha A Bakrania; Victoria deMartelly; Sarosh Rana; Sajid Shahul
Journal:  J Am Heart Assoc       Date:  2020-06-04       Impact factor: 5.501

5.  Prediction of preeclampsia risk in first time pregnant women: Metabolite biomarkers for a clinical test.

Authors:  Louise C Kenny; Grégoire Thomas; Lucilla Poston; Jenny E Myers; Nigel A B Simpson; Fergus P McCarthy; Leslie W Brown; Alison E Bond; Robin Tuytten; Philip N Baker
Journal:  PLoS One       Date:  2020-12-28       Impact factor: 3.240

6.  First-Trimester Sequential Screening for Preeclampsia Using Angiogenic Factors: Study Protocol for a Prospective, Multicenter, Real Clinical Setting Study.

Authors:  Cristina Trilla; Cristina Luna; Silvia De León Socorro; Leire Rodriguez; Aina Ruiz-Romero; Josefina Mora Brugués; Taysa Benítez Delgado; Marta Fabre; Alicia Martin Martínez; Sara Ruiz-Martinez; Elisa Llurba; Daniel Oros
Journal:  Front Cardiovasc Med       Date:  2022-07-26

7.  Evaluating adherence to American College of Obstetricians and Gynecologists guidelines at the first obstetric visit.

Authors:  Diane Christopher; Amy Markese; Shawna Tonick; Lauren Carpenter; Margo S Harrison
Journal:  Womens Health (Lond)       Date:  2022 Jan-Dec

8.  Maternal Vascular Health in Pregnancy and Postpartum After Assisted Reproduction.

Authors:  Frauke von Versen-Höynck; Sebastian Häckl; Elif Seda Selamet Tierney; Kirk P Conrad; Valerie L Baker; Virginia D Winn
Journal:  Hypertension       Date:  2019-12-16       Impact factor: 10.190

9.  Long-Term Postpartum Cardiac Function and Its Association With Preeclampsia.

Authors:  Victoria A deMartelly; John Dreixler; Avery Tung; Ariel Mueller; Sarah Heimberger; Abid A Fazal; Heba Naseem; Roberto Lang; Eric Kruse; Megan Yamat; Joey P Granger; Bhavisha A Bakrania; Javier Rodriguez-Kovacs; Sarosh Rana; Sajid Shahul
Journal:  J Am Heart Assoc       Date:  2021-02-23       Impact factor: 5.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.